Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived inhibitory antibody that can specifically target mouse CD8 molecules and deplete CD8 T cells, and is mainly applicable to research in fields such as cancer, inflammation, immunology, and metabolic diseases.

Trivalent GalNAc-DBCO is a synthetic ligand composed of three GalNAc units linked to DBCO. Trivalent GalNAc-DBCO undergoes strain-promoted alkyne–azide cycloaddition (SPAAC) reactions with azide-containing molecules without the need for copper catalysis. Trivalent GalNAc-DBCO binds specifically to the asialoglycoprotein receptor (ASGPR), thereby directing conjugated molecules into hepatocytes for lysosomal degradation through receptor-mediated endocytosis. Trivalent GalNAc-DBCO is extensively applied in studies of liver-targeted drug delivery, targeted degradation strategies, and hepatocyte-specific molecular engineering.

WSF1-IN-1 is an orally bioavailable small-molecule inhibitor of the WSF1 protein, designed for the investigation of WSF1-associated tumorigenesis in Wolfram syndrome. in studies using HepG2 parental and HepG2 WFS1 knockout cell lines, WSF1-IN-1 demonstrated differential inhibitory potency with IC50 values of 0.33 μM, confirming its target selectivity and mechanistic specificity in modulating WSF1-related cellular pathways.

Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is a humanized monoclonal antibody targeting Lysosomal-Associated Membrane Protein 1 (LAMP1/CD107a). LAMP1 is typically located on lysosomal membranes but is highly expressed on the surface of various solid tumor cells. Serving as the targeting moiety of the antibody-drug conjugate (ADC) SAR-428926, this antibody specifically binds to surface-expressed LAMP1, mediating the internalization of the ADC and the release of a potent maytansinoid cytotoxic payload. This targeting strategy demonstrates outstanding anti-tumor efficacy in patient-derived xenograft (PDX) models of solid tumors, effectively inhibiting tumor growth.

Anti-CD59 Antibody is a humanized monoclonal antibody targeting CD59 (Protectin/MAC-IP). CD59 is a GPI-anchored complement regulatory protein widely expressed on cell surfaces. It protects host cells from complement-mediated lysis by binding to complement components C8 and C9, thereby preventing the final assembly of the Membrane Attack Complex (MAC/C5b-9). CD59 is often overexpressed in various solid tumors and hematologic malignancies, enabling tumor cells to evade immune surveillance. This antibody specifically binds to CD59, blocking its inhibition of MAC assembly to restore tumor cell sensitivity to complement and induce potent Complement-Dependent Cytotoxicity (CDC). It serves as a critical tool for investigating tumor immune evasion and developing enhanced complement-based immunotherapies.

Anti-CD4 Antibody (TRX1) is a humanized, non-depleting monoclonal antibody targeting the CD4 receptor. The compound specifically binds to CD4 on T helper cells, inducing receptor down-modulation and T-cell anergy to establish immune tolerance without causing significant depletion of CD4+ T cells. It is utilized in clinical and experimental research for tolerance induction in autoimmune diseases and as an HIV entry inhibitor.

Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells that specifically targets AGER/RAGE.

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is a monoclonal antibody against mouse ICOSL/CD275. It inhibits the adhesion between T cells and endothelial cells, reduces the expansion of TR Treg cells, and is suitable for studies on inflammatory and infectious diseases such as influenza virus infection and arthritis.

Cergutuzumab (RG7813) is a tumor-targeted immunocytokine comprising a humanized anti-CEA monoclonal antibody fused to an engineered interleukin-2 variant (IL-2v). By specifically binding to Carcinoembryonic Antigen (CEA) on tumor cells, Cergutuzumab delivers IL-2v directly to the tumor microenvironment. This selectively activates cytotoxic CD8+ T cells and NK cells while minimizing the systemic toxicity typically associated with wild-type IL-2 therapy.